University of Cincinnati Medical Center is pleased to share with you Pulmonary Insights, an educational resource with information on the cutting-edge research, clinical trials, training and innovative treatments that are advancing the field.
Intra bronchial valves (IBVs) are FDA-approved to limit distal airflow to damaged lung tissue to aid in the reduction or cessation of persistent postoperative air leaks in pre-identified airways.
Read more →Successful completion of the Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Sirolimus (MILES) trial was critically dependent on communication and collaboration with the LAM patient community, which was made possible through their advocacy group, the LAM Foundation.
Read more →Until the 1990s, almost nothing was known about Lymphangioleiomyomatosis (LAM).
Read more →
Pulmonary alveolar proteinosis (PAP) was discovered in 1958 but it wasn’t until almost 40 years later that the pathogenesis of this rare lung syndrome was determined following the serendipitous discovery that mice deficient in granulocyte-macrophage colony-stimulating factor (GM-CSF) spontaneously develop PAP
Read more →
Responding to a congressional initiative to promote clinical research for rare diseases – that collectively affect approximately 25 million Americans – the National Institutes of Health (NIH) established the Rare Diseases Clinical Research Network (RDCRN) in 2003
Read more →
Lymphangioleiomyomatosis (LAM) is a rare, metastatic neoplasm in women that leads to cystic lung destruction and declining lung function. Until recently, LAM patients faced respiratory disability and the need for supplemental oxygen and lung transplantation without an effective therapy.
Read more →
